Appili Therapeutics Inc (TSX:APLI) Share Price

Company Profile

Business description
Appili Therapeutics Inc is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, it develops a pipeline of novel therapies to prevent deaths and improve lives. The company is advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its pipeline includes ATI-1701, ATI-1801, ATI-1501.
Contact
No. 21-1344 Summer Street
HalifaxNSB3H 0A8
CAN
T: +1 905 442-4655
https://www.appilitherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
7

Recommended

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,886.60	35.90	0.41%
CAC 40	8,082.60	4.12	0.05%
DAX 40	25,435.20	60.78	0.24%
Dow JONES (US)	51,481.51	347.11	-0.67%
FTSE 100	10,704.77	19.89	0.19%
HKSE	24,523.57	118.94	-0.48%
NASDAQ	26,820.38	248.34	-0.92%
Nikkei 225	65,481.27	396.35	-0.60%
NZX 50 Index	13,683.63	147.05	-1.06%
S&P 500	7,683.69	59.72	-0.77%
S&P/ASX 200	8,709.30	29.60	0.34%
SSE Composite Index	3,830.45	6.83	0.18%